1. Home
  2. AIIR vs NVAX Comparison

AIIR vs NVAX Comparison

Compare AIIR & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Air Global PLC Ordinary Shares

AIIR

Air Global PLC Ordinary Shares

N/A

Current Price

$7.80

Market Cap

1.2B

ML Signal

N/A

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$9.59

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIIR
NVAX
Founded
N/A
1987
Country
United Arab Emirates
United States
Employees
N/A
N/A
Industry
Tobacco
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2025
1996

Fundamental Metrics

Financial Performance
Metric
AIIR
NVAX
Price
$7.80
$9.59
Analyst Decision
Hold
Analyst Count
0
9
Target Price
N/A
$11.33
AVG Volume (30 Days)
8.3K
4.9M
Earning Date
N/A
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
309.76
EPS
N/A
N/A
Revenue
N/A
$1,123,479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
64.69
52 Week Low
$5.29
$6.20
52 Week High
$8.97
$11.85

Technical Indicators

Market Signals
Indicator
AIIR
NVAX
Relative Strength Index (RSI) 56.31 53.12
Support Level $6.63 $9.14
Resistance Level $8.59 $10.26
Average True Range (ATR) 0.89 0.63
MACD -0.04 0.03
Stochastic Oscillator 47.33 42.78

Price Performance

Historical Comparison
AIIR
NVAX

About AIIR Air Global PLC Ordinary Shares

AIR Global PLC operates in the social inhalation products sector and has operations across multiple international markets. Its portfolio includes businesses and products related to shisha and hookah, including flavored shisha molasses, hookah and shisha e-commerce platforms, and charcoal-free shisha devices. The company also conducts product research and testing in partnership with independent laboratories to support the development of inhalation-related products and technologies.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: